Cell surface markers in colorectal cancer prognosis

International Journal of Molecular Sciences

Volumn 12, Issue 1, 2011, Pages 78-113

  Belov, Larissa ^a   Zhou, Jerry ^a   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biomarkers; Colorectal cancer; Prognostic; Proteomics

Indexed keywords

ANNEXIN; CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; CELL SURFACE MARKER; CHEMOKINE RECEPTOR; CLAUDIN; DEATH RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; GROWTH FACTOR RECEPTOR; LECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MUCIN; TETRASPANIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; MEMBRANE PROTEIN; TUMOR MARKER;

CANCER CELL; CANCER STEM CELL; COLORECTAL CANCER; CONNECTIVE TISSUE TUMOR; HUMAN; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; OUTCOME ASSESSMENT; PROGNOSIS; PROTEOMICS; REVIEW; STROMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; COLORECTAL NEOPLASMS; DISEASE COURSE; METABOLISM; METASTASIS; SURVIVAL; TUMOR MICROENVIRONMENT;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTEOMICS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 79251612229     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12010078     Document Type: Review

References (285)

1. Puppa, G.; Sonzogni, A.; Colombari, R.; Pelosi, G. TNM staging system of colorectal carcinoma: A critical appraisal of challenging issues. Arch. Pathol. Lab. Med. 2010, 134, 837-852.
2. Zinkin, L.D. A critical review of the classifications and staging of colorectal cancer. Dis. Colon. Rectum. 1983, 26, 37-43.
3. Compton, C.C. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod. Pathol. 2003, 16, 376-388.
4. O'Connell, J.B.; Maggard, M.A.; Ko, C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 2004, 96, 1420-1425.
5. Alfonso, P.; Canamero, M.; Fernandez-Carbonie, F.; Nunez, A.; Casal, J.I. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J. Proteome Res. 2008, 7, 4247-4255.
6. Andre, M.; Le Caer, J.P.; Greco, C.; Planchon, S.; El Nemer, W.; Boucheix, C.; Rubinstein, E.; Chamot-Rooke, J.; Le Naour, F. Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics 2006, 6, 1437-1449.
7. Barderas, R.; Babel, I.; Casal, J.I. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics-Clin. Appl. Rev. 2010, 4, 159-178.
8. Friedman, D.B.; Hill, S.; Keller, J.W.; Merchant, N.B.; Levy, S.E.; Coffey, R.J.; Caprioli, R.M. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4, 793-811.
9. Gil-Bazo, I. Novel translational strategies in colorectal Cancer Res.earch. World J. Gastroenterol. 2007, 13, 5902-5910.
10. Habermann, J.K.; Bader, F.G.; Franke, C.; Zimmermann, K.; Gemoll, T.; Fritzsche, B.; Ried, T.; Auer, G.; Bruch, H.P.; Roblick, U.J. From the genome to the proteome--biomarkers in colorectal cancer. Langenbecks Arch. Surg. 2008, 393, 93-104.
11. Jimenez, C.R.; Knol, J.C.; Meijer, G.A.; Fijneman, R.J. Proteomics of colorectal cancer: Overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J. Proteomics 2010, 73, 1873-1895.
12. Luque-Garcia, J.L.; Martinez-Torrecuadrada, J.L.; Epifano, C.; Canamero, M.; Babel, I.; Casal, J.I. Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 2010, 10, 940-952.
13. Hlubek, F.; Brabletz, T.; Budczies, J.; Pfeiffer, S.; Jung, A.; Kirchner, T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int. J. Cancer 2007, 121, 1941-1948.
14. Li, J.Q.; Xu, B.J.; Shakhtour, B.; Deane, N.; Merchant, N.; Heslin, M.J.; Washington, K.; Coffey, R.J.; Beauchamp, R.D.; Shyr, Y.; Billheimer, D. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Int. J. Oncol. 2007, 31, 103-111.
15. Ahn, Y.H.; Lee, J.Y.; Kim, Y.S.; Ko, J.H.; Yoo, J.S. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J. Proteome Res. 2009, 8, 4216-4224.
16. Rho, J.H.; Qin, S.; Wang, J.Y.; Roehrl, M.H. Proteomic expression analysis of surgical human colorectal cancer tissues: Up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J. Proteome Res. 2008, 7, 2959-2572.
17. Petrak, J.; Ivanek, R.; Toman, O.; Cmejla, R.; Cmejlova, J.; Vyoral, D.; Zivny, J.; Vulpe, C.D. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008, 8, 1744-1749.
18. Wang, P.; Bouwman, F.G.; Mariman, E.C. Generally detected proteins in comparative proteomics--a matter of cellular stress response? Proteomics 2009, 9, 2955-2566.
19. Yamasaki, M.; Takemasa, I.; Komori, T.; Watanabe, S.; Sekimoto, M.; Doki, Y.; Matsubara, K.; Monden, M. The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int. J. Oncol. 2007, 30, 129-138.
20. Eschrich, S.; Yang, I.; Bloom, G.; Kwong, K.Y.; Boulware, D.; Cantor, A.; Coppola, D.; Kruhoffer, M.; Aaltonen, L.; Orntoft, T.F.; Quackenbush, J.; Yeatman, T.J. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 2005, 23, 3526-3535.
21. Ellmark, P.; Belov, L.; Huang, P.; Lee, C.S.; Solomon, M.J.; Morgan, D.K.; Christopherson, R.I. Multiplex detection of surface molecules on colorectal cancers. Proteomics 2006, 6, 1791-1802.
22. Zhou, J.; Belov, L.; Huang, P.Y.; Shin, J.S.; Solomon, M.J.; Chapuis, P.H.; Bokey, L.; Chan, C.; Clarke, C.; Clarke, S.J.; Christopherson, R.I. Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. J. Immunol. Methods 2010, 355, 40-51.
23. Belov, L.; Mulligan, S.P.; Barber, N.; Woolfson, A.; Scott, M.; Stoner, K.; Chrisp, J.S.; Sewell, W.A.; Bradstock, K.F.; Bendall, L.; Pascovici, D.S.; Thomas, M.; Erber, W.; Huang, P.; Sartor, M.; Young, G.A.; Wiley, J.S.; Juneja, S.; Wierda, W.G.; Green, A.R.; Keating, M.J.; Christopherson, R.I. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br. J. Haematol. 2006, 135, 184-197.
24. Moyret-Lalle, C.; Falette, N.; Grelier, G.; Puisieux, A. Tumour genomics: An unstable landscape. Bull Cancer 2008, 95, 923-930.
25. McAllister, S.S.; Weinberg, R.A. Tumor-Host Interactions: A Far-Reaching Relationship. J. Clin. Oncol. 2010, 28, 4022-4028.
26. Kaufman, K.L.; Mactier, S.; Kohnke, P.; Christopherson, R.I. Cell surface oncoproteomics: Cancer biomarker discovery and clinical applications. In Oncoproteins: Types and Detection; Davis, J.R., Ed.; Nova Science Publishes, Inc.: Hauppauge, NY, USA, 2010.
27. Leth-Larsen, R.; Lund, R.R.; Ditzel, H.J. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol. Cell Proteomics 2010, 9, 1369-1382.
28. Baldus, S.E.; Schaefer, K.L.; Engers, R.; Hartleb, D.; Stoecklein, N.H.; Gabbert, H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010, 16, 790-799.
29. Fang, J.Y.; Richardson, B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005, 6, 322-327.
30. Markowitz, S.D.; Bertagnolli, M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361, 2449-2460.
31. Saif, M.W.; Chu, E. Biology of colorectal cancer. Cancer J. 2010, 16, 196-201.
32. Sancho, E.; Batlle, E.; Clevers, H. Signaling pathways in intestinal development and cancer. 2004, 20, 695-723.
33. Wu, C.C.; Yates, J.R., III. The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 2003, 21, 262-267.
34. Bird, N.C.; Mangnall, D.; Majeed, A.W. Biology of colorectal liver metastases: A review. J. Surg. Oncol. 2006, 94, 68-80.
35. Haier, J.; Nasralla, M.; Nicolson, G.L. Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann. Surg. 2000, 231, 11-24.
36. De Wever, O.; Mareel, M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003, 200, 429-447.
37. Sund, M.; Kalluri, R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev. 2009, 28, 177-183.
38. Bacman, D.; Merkel, S.; Croner, R.; Papadopoulos, T.; Brueckl, W.; Dimmler, A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: A retrospective study. BMC Cancer 2007, 7, 156.
39. Kitadai, Y.; Sasaki, T.; Kuwai, T.; Nakamura, T.; Bucana, C.D.; Fidler, I.J. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am. J. Pathol. 2006, 169, 2054-2065.
40. Kitadai, Y.; Sasaki, T.; Kuwai, T.; Nakamura, T.; Bucana, C.D.; Hamilton, S.R.; Fidler, I.J. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int. J. Cancer 2006, 119, 2567-2574.
41. Saigusa, S.; Toiyama, Y.; Tanaka, K.; Yokoe, T.; Okugawa, Y.; Kawamoto, A.; Yasuda, H.; Inoue, Y.; Miki, C.; Kusunoki, M. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann. Surg. Oncol. 2010, 17, 2051-2058.
42. Henry, L.R.; Lee, H.O.; Lee, J.S.; Klein-Szanto, A.; Watts, P.; Ross, E.A.; Chen, W.T.; Cheng, J.D. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 2007, 13, 1736-1741.
43. Saito, K.; Takeha, S.; Shiba, K.; Matsuno, S.; Sorsa, T.; Nagura, H.; Ohtani, H. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: Functional multiplicity of matrix degradation on hematogenous metastasis. Int. J. Cancer 2000, 86, 24-29.
44. Mesker, W.E.; Liefers, G.J.; Junggeburt, J.M.; van Pelt, G.W.; Alberici, P.; Kuppen, P.J.; Miranda, N.F.; van Leeuwen, K.A.; Morreau, H.; Szuhai, K.; Tollenaar, R.A.; Tanke, H.J. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol. 2009, 31, 169-178.
45. Ogawa, H.; Iwaya, K.; Izumi, M.; Kuroda, M.; Serizawa, H.; Koyanagi, Y.; Mukai, K. Expression of CD10 by stromal cells during colorectal tumor development. Hum. Pathol. 2002, 33, 806-811.
46. Miyanaga, K.; Kato, Y.; Nakamura, T.; Matsumura, M.; Amaya, H.; Horiuchi, T.; Chiba, Y.; Tanaka, K. Expression and role of thrombospondin-1 in colorectal cancer. AntiCancer Res. 2002, 22, 3941-3948.
47. Kaio, E.; Tanaka, S.; Oka, S.; Hiyama, T.; Kitadai, Y.; Haruma, K.; Chayama, K. Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int. J. Oncol. 2003, 23, 901-911.
48. Maeda, K.; Nishiguchi, Y.; Kang, S.M.; Yashiro, M.; Onoda, N.; Sawada, T.; Ishikawa, T.; Hirakawa, K. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol. Rep. 2001, 8, 763-766.
49. Maeda, K.; Nishiguchi, Y.; Yashiro, M.; Yamada, S.; Onoda, N.; Sawada, T.; Kang, S.M.; Hirakawa, K. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int. J. Mol. Med. 2000, 5, 373-378.
50. Roberts, D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 1996, 10, 1183-1191.
51. Sutton, C.D.; O'Byrne, K.; Goddard, J.C.; Marshall, L.J.; Jones, L.; Garcea, G.; Dennison, A.R.; Poston, G.; Lloyd, D.M.; Berry, D.P. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin. Cancer Res. 2005, 11, 6567-6573.
52. Forssell, J.; Oberg, A.; Henriksson, M.L.; Stenling, R.; Jung, A.; Palmqvist, R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. 2007, 13, 1472-1479.
53. Klintrup, K.; Makinen, J.M.; Kauppila, S.; Vare, P.O.; Melkko, J.; Tuominen, H.; Tuppurainen, K.; Makela, J.; Karttunen, T.J.; Makinen, M.J. Inflammation and prognosis in colorectal cancer. Eur. J. Cancer 2005, 41, 2645-2654.
54. Jedinak, A.; Dudhgaonkar, S.; Sliva, D. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 2010, 215, 242-249.
55. Kaler, P.; Galea, V.; Augenlicht, L.; Klampfer, L. Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One 2010, 5, e11700.
56. Yuan, A.; Chen, J.J.; Yang, P.C. Pathophysiology of tumor-associated macrophages. Adv Clin. Chem. 2008, 45, 199-223.
57. Jedinak, A.; Dudhgaonkar, S.; Sliva, D. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 2010, 215, 242-249.
58. Sandel, M.H.; Dadabayev, A.R.; Menon, A.G.; Morreau, H.; Melief, C.J.; Offringa, R.; van der Burg, S.H.; Janssen-van Rhijn, C.M.; Ensink, N.G.; Tollenaar, R.A.; van de Velde, C.J.; Kuppen, P.J. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: Role of maturation status and intratumoral localization. Clin. Cancer Res. 2005, 11, 2576-2582.
59. Camus, M.; Tosolini, M.; Mlecnik, B.; Pages, F.; Kirilovsky, A.; Berger, A.; Costes, A.; Bindea, G.; Charoentong, P.; Bruneval, P.; Trajanoski, Z.; Fridman, W.H.; Galon, J. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009, 69, 2685-2693.
60. Nagorsen, D.; Voigt, S.; Berg, E.; Stein, H.; Thiel, E.; Loddenkemper, C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: Relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J. Transl. Med. 2007, 5, 62.
61. Adams, H.; Tzankov, A.; Lugli, A.; Zlobec, I. New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. J. Clin. Pathol. 2009, 62, 986-997.
62. Jass, J.R.; Ajioka, Y.; Allen, J.P.; Chan, Y.F.; Cohen, R.J.; Nixon, J.M.; Radojkovic, M.; Restall, A.P.; Stables, S.R.; Zwi, L.J. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 1996, 28, 543-548.
63. Katz, S.C.; Pillarisetty, V.; Bamboat, Z.M.; Shia, J.; Hedvat, C.; Gonen, M.; Jarnagin, W.; Fong, Y.; Blumgart, L.; D'Angelica, M.; DeMatteo, R.P. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann. Surg. Oncol. 2009, 16, 2524-2530.
64. Ohtani, H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007, 7, 4.
65. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Pages, F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
66. Lee, W.S.; Park, S.; Lee, W.Y.; Yun, S.H.; Chun, H.K. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010, 116, 5188-5199.
67. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8 T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58, 3491-3494.
68. Pages, F.; Galon, J.; Dieu-Nosjean, M.C.; Tartour, E.; Sautes-Fridman, C.; Fridman, W.H. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene 2010, 29, 1093-1102.
69. Strater, J.; Herter, I.; Merkel, G.; Hinz, U.; Weitz, J.; Moller, P. Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: Caspase-8 and caspase-9 is associated with poor prognosis. Int. J. Cancer 2010, 127, 873-880.
70. Deschoolmeester, V.; Baay, M.; Specenier, P.; Lardon, F.; Vermorken, J.B. A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy. Oncologist 2010, 15, 699-731.
71. Galon, J.; Fridman, W.H.; Pages, F. The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res. 2007, 67, 1883-1886.
72. Halama, N.; Michel, S.; Kloor, M.; Zoernig, I.; Pommerencke, T.; von Knebel Doeberitz, M.; Schirmacher, P.; Weitz, J.; Grabe, N.; Jager, D. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009, 9, 1.
73. Pages, F.; Galon, J.; Fridman, W.H. The essential role of the in situ immune reaction in human colorectal cancer. J. Leukoc Biol. 2008, 84, 981-987.
74. Simpson, J.A.; Al-Attar, A.; Watson, N.F.; Scholefield, J.H.; Ilyas, M.; Durrant, L.G. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 2010, 59, 926-933.
75. Laghi, L.; Bianchi, P.; Miranda, E.; Balladore, E.; Pacetti, V.; Grizzi, F.; Allavena, P.; Torri, V.; Repici, A.; Santoro, A.; Mantovani, A.; Roncalli, M.; Malesci, A. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: A longitudinal study. Lancet Oncol. 2009, 10, 877-884.
76. Diederichsen, A.C.; Hjelmborg, J.B.; Christensen, P.B.; Zeuthen, J.; Fenger, C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother. 2003, 52, 423-428.
77. Dolcetti, R.; Viel, A.; Doglioni, C.; Russo, A.; Guidoboni, M.; Capozzi, E.; Vecchiato, N.; Macri, E.; Fornasarig, M.; Boiocchi, M. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. 1999, 154, 1805-1813.
78. Prall, F.; Duhrkop, T.; Weirich, V.; Ostwald, C.; Lenz, P.; Nizze, H.; Barten, M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 2004, 35, 808-816.
79. Clark, A.J.; Barnetson, R.; Farrington, S.M.; Dunlop, M.G. Prognosis in DNA mismatch repair deficient colorectal cancer: Are all MSI tumours equivalent? Fam. Cancer 2004, 3, 85-91.
80. Menon, A.G.; Janssen-van Rhijn, C.M.; Morreau, H.; Putter, H.; Tollenaar, R.A.; van de Velde, C.J.; Fleuren, G.J.; Kuppen, P.J. Immune system and prognosis in colorectal cancer: A detailed immunohistochemical analysis. Lab. Invest. 2004, 84, 493-501.
81. Nussler, N.C.; Strange, B.J.; Petzold, M.; Nussler, A.K.; Glanemann, M.; Guckelberger, O. Reduced NK-cell activity in patients with metastatic colon cancer. EXCLI J. 2007, 6, 1-9.
82. Koch, M.; Beckhove, P.; Op den Winkel, J.; Autenrieth, D.; Wagner, P.; Nummer, D.; Specht, S.; Antolovic, D.; Galindo, L.; Schmitz-Winnenthal, F.H.; Schirrmacher, V.; Buchler, M.W.; Weitz, J. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann. Surg. 2006, 244, 986-992.
83. Salama, P.; Phillips, M.; Grieu, F.; Morris, M.; Zeps, N.; Joseph, D.; Platell, C.; Iacopetta, B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009, 27, 186-192.
84. Kitayama, J.; Nagawa, H.; Nakayama, H.; Tuno, N.; Shibata, Y.; Muto, T. Functional expression of beta1 and beta2 integrins on tumor infiltrating lymphocytes (TILs) in colorectal cancer. J. Gastroenterol. 1999, 34, 327-333.
85. Kruger, K.; Buning, C.; Schriever, F. Activated T lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells. Eur. J. Immunol. 2001, 31, 138-145.
86. Berndt, U.; Philipsen, L.; Bartsch, S.; Wiedenmann, B.; Baumgart, D.C.; Hammerle, M.; Sturm, A. Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. Cancer Res. 2008, 68, 880-888.
87. Diederichsen, A.C.; Zeuthen, J.; Christensen, P.B.; Kristensen, T. Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur. J. Cancer 1999, 35, 721-726.
88. Sinicrope, F.A.; Rego, R.L.; Ansell, S.M.; Knutson, K.L.; Foster, N.R.; Sargent, D.J. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137, 1270-1279.
89. Suzuki, H.; Chikazawa, N.; Tasaka, T.; Wada, J.; Yamasaki, A.; Kitaura, Y.; Sozaki, M.; Tanaka, M.; Onishi, H.; Morisaki, T.; Katano, M. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immunother. 2010, 59, 653-661.
90. Correale, P.; Rotundo, M.S.; Del Vecchio, M.T.; Remondo, C.; Migali, C.; Ginanneschi, C.; Tsang, K.Y.; Licchetta, A.; Mannucci, S.; Loiacono, L.; Tassone, P.; Francini, G.; Tagliaferri, P. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 2010, 33, 435-441.
91. Frey, D.M.; Droeser, R.A.; Viehl, C.T.; Zlobec, I.; Lugli, A.; Zingg, U.; Oertli, D.; Kettelhack, C.; Terracciano, L.; Tornillo, L. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 2010, 126, 2635-2643.
92. Hashida, H.; Takabayashi, A.; Tokuhara, T.; Hattori, N.; Taki, T.; Hasegawa, H.; Satoh, S.; Kobayashi, N.; Yamaoka, Y.; Miyake, M. Clinical significance of transmembrane 4 superfamily in colon cancer. Br. J. Cancer 2003, 89, 158-167.
93. Le Naour, F.; Andre, M.; Boucheix, C.; Rubinstein, E. Membrane microdomains and proteomics: Lessons from tetraspanin microdomains and comparison with lipid rafts. Proteomics 2006, 6, 6447-6454.
94. Le Naour, F.; Andre, M.; Greco, C.; Billard, M.; Sordat, B.; Emile, J.F.; Lanza, F.; Boucheix, C.; Rubinstein, E. Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell Proteomics 2006, 5, 845-857.
95. Yanez-Mo, M.; Barreiro, O.; Gordon-Alonso, M.; Sala-Valdes, M.; Sanchez-Madrid, F. Tetraspanin-enriched microdomains: A functional unit in cell plasma membranes. Trends Cell Biol. 2009, 19, 434-446.
96. Zoller, M. Gastrointestinal tumors: Metastasis and tetraspanins. Z Gastroenterol. 2006, 44, 573-586.
97. Mori, M.; Mimori, K.; Shiraishi, T.; Haraguchi, M.; Ueo, H.; Barnard, G.F.; Akiyoshi, T. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin. Cancer Res. 1998, 4, 1507-1510.
98. El-Bahrawy, M.; Poulsom, R.; Rowan, A.J.; Tomlinson, I.T.; Alison, M.R. Characterization of the E-cadherin/catenin complex in colorectal carcinoma cell lines. Int. J. Exp. Pathol. 2004, 85, 65-74.
99. Boo, Y.J.; Park, J.M.; Kim, J.; Chae, Y.S.; Min, B.W.; Um, J.W.; Moon, H.Y. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann. Surg. Oncol. 2007, 14, 1703-1711.
100. Mohri, Y. Prognostic significance of E-cadherin expression in human colorectal cancer tissue. Surg. Today 1997, 27, 606-612.
101. Tsanou, E.; Peschos, D.; Batistatou, A.; Charalabopoulos, A.; Charalabopoulos, K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. AntiCancer Res. 2008, 28, 3815-3826.
102. Hayashida, Y.; Honda, K.; Idogawa, M.; Ino, Y.; Ono, M.; Tsuchida, A.; Aoki, T.; Hirohashi, S.; Yamada, T. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res. 2005, 65, 8836-8845.
103. Wanitsuwan, W.; Kanngurn, S.; Boonpipattanapong, T.; Sangthong, R.; Sangkhathat, S. Overall expression of beta-catenin outperforms its nuclear accumulation in predicting outcomes of colorectal cancers. World J. Gastroenterol. 2008, 14, 6052-6059.
104. Fang, Q.X.; Lu, L.Z.; Yang, B.; Zhao, Z.S.; Wu, Y.; Zheng, X.C. L1, beta-catenin, and E-cadherin expression in patients with colorectal cancer: Correlation with clinicopathologic features and its prognostic significance. J. Surg. Oncol. 2010, 102, 433-442.
105. Hashida, H.; Takabayashi, A.; Tokuhara, T.; Taki, T.; Kondo, K.; Kohno, N.; Yamaoka, Y.; Miyake, M. Integrin alpha3 expression as a prognostic factor in colon cancer: Association with MRP-1/CD9 and KAI1/CD82. Int. J. Cancer 2002, 97, 518-525.
106. Fujita, S.; Watanabe, M.; Kubota, T.; Teramoto, T.; Kitajima, M. Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 1995, 91, 145-149.
107. Gao, X.Q.; Han, J.X.; Xu, Z.F.; Zhang, W.D.; Zhang, H.N.; Huang, H.Y. Identification of the differential expressive tumor associated genes in rectal cancers by cDNA microarray. World J. Gastroenterol. 2007, 13, 341-348.
108. Okazaki, K.; Nakayama, Y.; Shibao, K.; Hirata, K.; Nagata, N.; Itoh, H. Enhancement of metastatic activity of colon cancer as influenced by expression of cell surface antigens. J. Surg. Res. 1998, 78, 78-84.
109. Herlevsen, M.; Schmidt, D.S.; Miyazaki, K.; Zoller, M. The association of the tetraspanin D6.1A with the alpha6beta4 integrin supports cell motility and liver metastasis formation. J. Cell Sci. 2003, 116, 4373-4390.
110. Mulder, J.W.; Kruyt, P.M.; Sewnath, M.; Oosting, J.; Seldenrijk, C.A.; Weidema, W.F.; Offerhaus, G.J.; Pals, S.T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994, 344, 1470-1472.
111. Ropponen, K.M.; Eskelinen, M.J.; Lipponen, P.K.; Alhava, E.; Kosma, V.M. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand. J. Gastroenterol. 1998, 33, 301-309.
112. Vizoso, F.J.; Fernandez, J.C.; Corte, M.D.; Bongera, M.; Gava, R.; Allende, M.T.; Garcia-Muniz, J.L.; Garcia-Moran, M. Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer. J. Cancer Res. Clin. Oncol. 2004, 130, 679-686.
113. Ngan, C.Y.; Yamamoto, H.; Seshimo, I.; Ezumi, K.; Terayama, M.; Hemmi, H.; Takemasa, I.; Ikeda, M.; Sekimoto, M.; Monden, M. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J. Surg. Oncol. 2007, 95, 652-662.
114. Kikuchi, R.; Noguchi, T.; Takeno, S.; Kubo, N.; Uchida, Y. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br. J. Cancer 2000, 83, 215-218.
115. Malhotra, S.; Newman, E.; Eisenberg, D.; Scholes, J.; Wieczorek, R.; Mignatti, P.; Shamamian, P. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: A possible mechanism of neoplastic progression. Dis. Colon. Rectum. 2002, 45, 537-543.
116. Shiomi, T.; Okada, Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003, 22, 145-152.
117. Mulder, W.M.; Stern, P.L.; Stukart, M.J.; de Windt, E.; Butzelaar, R.M.; Meijer, S.; Ader, H.J.; Claessen, A.M.; Vermorken, J.B.; Meijer, C.J.; Wagstaff, J.; Scheper, R.J.; Bloemena, E. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin. Cancer Res. 1997, 3, 1923-1930.
118. Maeda, K.; Kang, S.M.; Sawada, T.; Nishiguchi, Y.; Yashiro, M.; Ogawa, Y.; Ohira, M.; Ishikawa, T.; Hirakawa, Y.S.C.K. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol. Rep. 2002, 9, 511-514.
119. Chaudry, M.A.; Sales, K.; Ruf, P.; Lindhofer, H.; Winslet, M.C. EpCAM an immunotherapeutic target for gastrointestinal malignancy: Current experience and future challenges. Br. J. Cancer 2007, 96, 1013-1019.
120. Gosens, M.J.; van Kempen, L.C.; van de Velde, C.J.; van Krieken, J.H.; Nagtegaal, I.D. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod. Pathol. 2007, 20, 221-232.
121. Baeuerle, P.A.; Gires, O. EpCAM (CD326) finding its role in cancer. Br. J. Cancer 2007, 96, 417-423.
122. Munz, M.; Baeuerle, P.A.; Gires, O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009, 69, 5627-5629.
123. Shiah, S.-G.; Tai, K.-Y.; Wu, C.-W. Epigenetic regulation of EpCAM in tumor invasion and metastasis. J. Cancer Mol. 2008, 3, 165-168.
124. Trzpis, M.; McLaughlin, P.M.; de Leij, L.M.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386-395.
125. Winter, M.J.; Nagtegaal, I.D.; van Krieken, J.H.; Litvinov, S.V. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol. 2003, 163, 2139-2148.
126. Ohmachi, T.; Tanaka, F.; Mimori, K.; Inoue, H.; Yanaga, K.; Mori, M. Clinical significance of TROP2 expression in colorectal cancer. Clin. Cancer Res. 2006, 12, 3057-3063.
127. Ziegler, A.; Heidenreich, R.; Braumuller, H.; Wolburg, H.; Weidemann, S.; Mocikat, R.; Rocken, M. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009, 113, 3494-3502.
128. Rao, C.G.; Chianese, D.; Doyle, G.V.; Miller, M.C.; Russell, T.; Sanders, R.A., Jr.; Terstappen, L.W. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol. 2005, 27, 49-57.
129. Maetzel, D.; Denzel, S.; Mack, B.; Canis, M.; Went, P.; Benk, M.; Kieu, C.; Papior, P.; Baeuerle, P.A.; Munz, M.; Gires, O. Nuclear signalling by tumour-associated antigen EpCAM. Nat. Cell Biol. 2009, 11, 162-171.
130. Brabletz, T.; Jung, A.; Reu, S.; Porzner, M.; Hlubek, F.; Kunz-Schughart, L.A.; Knuechel, R.; Kirchner, T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 2001, 98, 10356-10361.
131. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454.
132. Ueno, H.; Murphy, J.; Jass, J.R.; Mochizuki, H.; Talbot, I.C. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002, 40, 127-132.
133. Zlobec, I.; Lugli, A. Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors. World J. Gastroenterol. 2009, 15, 5898-5906.
134. Hostettler, L.; Zlobec, I.; Terracciano, L.; Lugli, A. ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J. Gastroenterol. 2010, 16, 732-739.
135. Kuhn, S.; Koch, M.; Nubel, T.; Ladwein, M.; Antolovic, D.; Klingbeil, P.; Hildebrand, D.; Moldenhauer, G.; Langbein, L.; Franke, W.W.; Weitz, J.; Zoller, M. A Complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol. Cancer Res. 2007, 5, 553-567.
136. Nubel, T.; Preobraschenski, J.; Tuncay, H.; Weiss, T.; Kuhn, S.; Ladwein, M.; Langbein, L.; Zoller, M. Claudin-7 regulates EpCAM-mediated functions in tumor progression. Mol. Cancer Res. 2009, 7, 285-299.
137. Brockhausen, I. Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 2006, 7, 599-604.
138. Hollingsworth, M.A.; Swanson, B.J. Mucins in cancer: Protection and control of the cell surface. Nat. Rev. Cancer 2004, 4, 45-60.
139. Kufe, D.W. Mucins in cancer: Function, prognosis and therapy. Nat. Rev. Cancer 2009, 9, 874-885.
140. Farhat, M.H.; Barada, K.A.; Tawil, A.N.; Itani, D.M.; Hatoum, H.A.; Shamseddine, A.I. Effect of mucin production on survival in colorectal cancer: A case-control study. World J. Gastroenterol. 2008, 14, 6981-6985.
141. Baldus, S.E.; Monig, S.P.; Hanisch, F.G.; Zirbes, T.K.; Flucke, U.; Oelert, S.; Zilkens, G.; Madejczik, B.; Thiele, J.; Schneider, P.M.; Holscher, A.H.; Dienes, H.P. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002, 40, 440-449.
142. Hiraga, Y.; Tanaka, S.; Haruma, K.; Yoshihara, M.; Sumii, K.; Kajiyama, G.; Shimamoto, F.; Kohno, N. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998, 55, 307-319.
143. Saeland, E.; van Vliet, S.J.; Backstrom, M.; van den Berg, V.C.; Geijtenbeek, T.B.; Meijer, G.A.; van Kooyk, Y. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol. Immunother. 2007, 56, 1225-1236.
144. Itzkowitz, S.H.; Yuan, M.; Montgomery, C.K.; Kjeldsen, T.; Takahashi, H.K.; Bigbee, W.L.; Kim, Y.S. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989, 49, 197-204.
145. Iwasa, S.; Okada, K.; Chen, W.T.; Jin, X.; Yamane, T.; Ooi, A.; Mitsumata, M. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett. 2005, 227, 229-236.
146. Perez, R.O.; Bresciani, B.H.; Bresciani, C.; Proscurshim, I.; Kiss, D.; Gama-Rodrigues, J.; Pereira, D.D.; Rawet, V.; Cecconnello, I.; Habr-Gama, A. Mucinous colorectal adenocarcinoma: Influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis. Int. J. Colorectal. Dis. 2008, 23, 757-765.
147. Doekhie, F.S.; Morreau, H.; de Bock, G.H.; Speetjens, F.M.; Dekker-Ensink, N.G.; Putter, H.; van de Velde, C.J.; Tollenaar, R.A.; Kuppen, P.J. Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer Microenviron. 2008, 1, 141-151.
148. Gunther, K.; Dworak, O.; Remke, S.; Pfluger, R.; Merkel, S.; Hohenberger, W.; Reymond, M.A. Prediction of distant metastases after curative surgery for rectal cancer. J. Surg. Res. 2002, 103, 68-78.
149. Nakagoe, T.; Fukushima, K.; Hirota, M.; Kusano, H.; Ayabe, H.; Tomita, M.; Kamihira, S. Immunohistochemical expression of sialyl Lex antigen in relation to survival of patients with colorectal carcinoma. Cancer 1993, 72, 2323-2330.
150. Nakamori, S.; Kameyama, M.; Imaoka, S.; Furukawa, H.; Ishikawa, O.; Sasaki, Y.; Kabuto, T.; Iwanaga, T.; Matsushita, Y.; Irimura, T. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study. Cancer Res. 1993, 53, 3632-3637.
151. Matsui, T.; Kojima, H.; Suzuki, H.; Hamajima, H.; Nakazato, H.; Ito, K.; Nakao, A.; Sakamoto, J. Sialyl Lewisa expression as a predictor of the prognosis of colon carcinoma patients in a prospective randomized clinical trial. Jpn. J. Clin. Oncol. 2004, 34, 588-593.
152. Borsig, L.; Wong, R.; Hynes, R.O.; Varki, N.M.; Varki, A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. USA 2002, 99, 2193-2198.
153. Kannagi, R. Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med. J. 2007, 30, 189-209.
154. Kohler, S.; Ullrich, S.; Richter, U.; Schumacher, U. E-/P-selectins and colon carcinoma metastasis: First in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br. J. Cancer 2010, 102, 602-609.
155. Napier, S.L.; Healy, Z.R.; Schnaar, R.L.; Konstantopoulos, K. Selectin ligand expression regulates the initial vascular interactions of colon carcinoma cells: The roles of CD44v and alternative sialofucosylated selectin ligands. J. Biol. Chem. 2007, 282, 3433-3441.
156. Endo, K.; Kohnoe, S.; Tsujita, E.; Watanabe, A.; Nakashima, H.; Baba, H.; Maehara, Y. Galectin-3 expression is a potent prognostic marker in colorectal cancer. AntiCancer Res. 2005, 25, 3117-3121.
157. Nagy, N.; Legendre, H.; Engels, O.; Andre, S.; Kaltner, H.; Wasano, K.; Zick, Y.; Pector, J.C.; Decaestecker, C.; Gabius, H.J.; Salmon, I.; Kiss, R. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003, 97, 1849-1858.
158. Legendre, H.; Decaestecker, C.; Nagy, N.; Hendlisz, A.; Schuring, M.P.; Salmon, I.; Gabius, H.J.; Pector, J.C.; Kiss, R. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod. Pathol. 2003, 16, 491-504.
159. Song, S.; Byrd, J.C.; Mazurek, N.; Liu, K.; Koo, J.S.; Bresalier, R.S. Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1 activation. Gastroenterology 2005, 129, 1581-1591.
160. Bresalier, R.S.; Byrd, J.C.; Wang, L.; Raz, A. Colon cancer mucin: A new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res. 1996, 56, 4354-4357.
161. Dudas, S.P.; Yunker, C.K.; Sternberg, L.R.; Byrd, J.C.; Bresalier, R.S. Expression of human intestinal mucin is modulated by the beta-galactoside binding protein galectin-3 in colon cancer. Gastroenterology 2002, 123, 817-826.
162. Iwase, T.; Kushima, R.; Mukaisho, K.; Mitsufuji, S.; Okanoue, T.; Hattori, T. Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol. Res. Pract. 2005, 201, 83-91.
163. Jantscheff, P.; Terracciano, L.; Lowy, A.; Glatz-Krieger, K.; Grunert, F.; Micheel, B.; Brummer, J.; Laffer, U.; Metzger, U.; Herrmann, R.; Rochlitz, C. Expression of CEACAM6 in resectable colorectal cancer: A factor of independent prognostic significance. J. Clin. Oncol. 2003, 21, 3638-3646.
164. Cosimelli, M.; De Peppo, F.; Castelli, M.; Giannarelli, D.; Schinaia, G.; Castaldo, P.; Buttini, G.L.; Sciarretta, F.; Bigotti, G.; Di Filippo, F.; et al. Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients. A preliminary finding. Dis. Colon. Rectum. 1989, 32, 389-397.
165. Kim, J.C.; Han, M.S.; Lee, H.K.; Kim, W.S.; Park, S.K.; Park, K.C.; Bodmer, W.F.; Rowan, A.J.; Kim, O.J. Distribution of carcinoembryonic antigen and biologic behavior in colorectal carcinoma. Dis. Colon. Rectum. 1999, 42, 640-648.
166. Lorenzi, M.; Vindigni, C.; Minacci, C.; Tripodi, S. A.; Iroatulam, A.; Petrioli, R.; Francini, G. Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer. Int. J. Biol. Markers 1997, 12, 68-74.
167. Nazato, D.M.; Matos, L.L.; Waisberg, D.R.; Souza, J.R.; Martins, L.C.; Waisberg, J. Prognostic value of carcinoembryonic antigen distribution in tumor tissue of colorectal carcinoma. Arq. Gastroenterol. 2009, 46, 26-31.
168. Vogel, I.; Francksen, H.; Soeth, E.; Henne-Bruns, D.; Kremer, B.; Juhl, H. The carcinoembryonic antigen and its prognostic impact on immunocytologically detected intraperitoneal colorectal cancer cells. Am. J. Surg. 2001, 181, 188-193.
169. Hostetter, R.B.; Augustus, L.B.; Mankarious, R.; Chi, K.F.; Fan, D.; Toth, C.; Thomas, P.; Jessup, J.M. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J. Natl. Cancer Inst. 1990, 82, 380-385.
170. Blumenthal, R.D.; Hansen, H.J.; Goldenberg, D.M. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res. 2005, 65, 8809-8817.
171. Messick, C.A.; Sanchez, J.; Dejulius, K.L.; Hammel, J.; Ishwaran, H.; Kalady, M.F. CEACAM-7: A predictive marker for rectal cancer recurrence. Surgery 2010, 147, 713-719.
172. Duncan, R.; Carpenter, B.; Main, L.C.; Telfer, C.; Murray, G.I. Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer 2008, 98, 426-433.
173. Emoto, K.; Yamada, Y.; Sawada, H.; Fujimoto, H.; Ueno, M.; Takayama, T.; Kamada, K.; Naito, A.; Hirao, S.; Nakajima, Y. Annexin II over expression correlates with stromal tenascin-C over expression: A prognostic marker in colorectal carcinoma. Cancer 2001, 92, 1419-1426.
174. Xue, G.; Hao, L.Q.; Ding, F.X.; Mei, Q.; Huang, J.J.; Fu, C.G.; Yan, H.L.; Sun, S.H. Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas. J. Clin. Gastroenterol. 2009, 43, 831-837.
175. Tsukita, S.; Yamazaki, Y.; Katsuno, T.; Tamura, A. Tight junction-based epithelial micro environment and cell proliferation. Oncogene 2008, 27, 6930-6938.
176. de Oliveira, S.S.; de Oliveira, I.M.; De Souza, W.; Morgado-Diaz, J.A. Claudins upregulation in human colorectal cancer. FEBS Lett. 2005, 579, 6179-6185.
177. Resnick, M.B.; Konkin, T.; Routhier, J.; Sabo, E.; Pricolo, V.E. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: A tissue microarray study. Mod. Pathol. 2005, 18, 511-518.
178. Ueda, J.; Semba, S.; Chiba, H.; Sawada, N.; Seo, Y.; Kasuga, M.; Yokozaki, H. Heterogeneous expression of claudin-4 in human colorectal cancer: Decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 2007, 74, 32-41.
179. Cambien, B.; Karimdjee, B.F.; Richard-Fiardo, P.; Bziouech, H.; Barthel, R.; Millet, M.A.; Martini, V.; Birnbaum, D.; Scoazec, J.Y.; Abello, J.; Al Saati, T.; Johnson, M.G.; Sullivan, T.J.; Medina, J.C.; Collins, T.L.; Schmid-Alliana, A.; Schmid-Antomarchi, H. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br. J. Cancer 2009, 100, 1755-1764.
180. Kawada, K.; Hosogi, H.; Sonoshita, M.; Sakashita, H.; Manabe, T.; Shimahara, Y.; Sakai, Y.; Takabayashi, A.; Oshima, M.; Taketo, M.M. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007, 26, 4679-4688.
181. Kim, J.; Takeuchi, H.; Lam, S.T.; Turner, R.R.; Wang, H.J.; Kuo, C.; Foshag, L.; Bilchik, A.J.; Hoon, D.S. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J. Clin. Oncol. 2005, 23, 2744-2753.
182. Schimanski, C.C.; Galle, P.R.; Moehler, M. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J. Gastroenterol. 2008, 14, 4721-4724.
183. Gelmini, S.; Mangoni, M.; Serio, M.; Romagnani, P.; Lazzeri, E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J. Endocrinol. Invest. 2008, 31, 809-819.
184. Zimmermann, T.; Moehler, M.; Gockel, I.; Sgourakis, G.G.; Biesterfeld, S.; Muller, M.; Berger, M.R.; Lang, H.; Galle, P.R.; Schimanski, C.C. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int. J. Colorectal. Dis. 2010, 25, 417-4124.
185. de Castro-Carpeno, J.; Belda-Iniesta, C.; Casado Saenz, E.; Hernandez Agudo, E.; Feliu Batlle, J.; Gonzalez Baron, M. EGFR and colon cancer: A clinical view. Clin. Transl. Oncol. 2008, 10, 6-13.
186. Dasari, A.; Messersmith, W.A. New strategies in colorectal cancer: Biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin. Cancer Res. 2010, 16, 3811-3818.
187. Markman, B.; Capdevila, J.; Elez, E.; Tabernero, J. New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy 2009, 1, 965-982.
188. Azria, D.; Bibeau, F.; Barbier, N.; Zouhair, A.; Lemanski, C.; Rouanet, P.; Ychou, M.; Senesse, P.; Ozsahin, M.; Pelegrin, A.; Dubois, J.B.; Thezenas, S. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005, 5, 62.
189. Galizia, G.; Lieto, E.; Ferraraccio, F.; De Vita, F.; Castellano, P.; Orditura, M.; Imperatore, V.; La Mura, A.; La Manna, G.; Pinto, M.; Catalano, G.; Pignatelli, C.; Ciardiello, F. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann. Surg. Oncol. 2006, 13, 823-835.
190. Spano, J.P.; Lagorce, C.; Atlan, D.; Milano, G.; Domont, J.; Benamouzig, R.; Attar, A.; Benichou, J.; Martin, A.; Morere, J.F.; Raphael, M.; Penault-Llorca, F.; Breau, J.L.; Fagard, R.; Khayat, D.; Wind, P. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005, 16, 102-108.
191. Arkom, C.; Preecha, R.; Anant, K. Soisuda, S.; Sangduan, P.; Suleeporn, S. Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer (Institutional series). Cancer Ther. 2007, 5, 137-142.
192. Doger, F.K.; Meteoglu, I.; Tuncyurek, P.; Okyay, P.; Cevikel, H. Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur. Surg. Res. 2006, 38, 540-544.
193. Zhang, C.; Hao, L.; Wang, L.; Xiao, Y.; Ge, H.; Zhu, Z.; Luo, Y.; Zhang, Y. Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. BMC Cancer 2010, 10, 184.
194. Osako, T.; Miyahara, M.; Uchino, S.; Inomata, M.; Kitano, S.; Kobayashi, M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998, 55, 548-555.
195. Kavanagh, D.O.; Chambers, G.; O'Grady, L.; Barry, K.M.; Waldron, R.P.; Bennani, F.; Eustace, P.W.; Tobbia, I. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009, 9, 1.
196. Baiocchi, G.; Lopes, A.; Coudry, R.A.; Rossi, B.M.; Soares, F.A.; Aguiar, S.; Guimaraes, G.C.; Ferreira, F.O.; Nakagawa, W.T. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int. J. Colorectal. Dis. 2009, 24, 1059-1068.
197. De Oliveira, A.T.; Matos, D.; Logullo, A.F.; SR, D.A.S.; Neto, R.A.; Filho, A.L.; Saad, S.S. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. AntiCancer Res. 2009, 29, 4807-4811.
198. Ginty, F.; Adak, S.; Can, A.; Gerdes, M.; Larsen, M.; Cline, H.; Filkins, R.; Pang, Z.; Li, Q.; Montalto, M.C. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin. Cancer Res. 2008, 14, 3814-3822.
199. Johnstone, R.W.; Frew, A.J.; Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8, 782-798.
200. Strater, J.; Hinz, U.; Walczak, H.; Mechtersheimer, G.; Koretz, K.; Herfarth, C.; Moller, P.; Lehnert, T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 2002, 8, 3734-3740.
201. Bavi, P.; Prabhakaran, S.E.; Abubaker, J.; Qadri, Z.; George, T.; Al-Sanea, N.; Abduljabbar, A.; Ashari, L.H.; Alhomoud, S.; Al-Dayel, F.; Hussain, A.R.; Uddin, S.; Al-Kuraya, K.S. Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol. Cancer 2010, 9, 203.
202. van Geelen, C.M.; Westra, J.L.; de Vries, E.G.; Boersma-van Ek, W.; Zwart, N.; Hollema, H.; Boezen, H.M.; Mulder, N.H.; Plukker, J.T.; de Jong, S.; Kleibeuker, J.H.; Koornstra, J.J. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J. Clin. Oncol. 2006, 24, 4998-5004.
203. McLornan, D.P.; Barrett, H.L.; Cummins, R.; McDermott, U.; McDowell, C.; Conlon, S.J.; Coyle, V.M.; van Schaeybroeck, S.; Wilson, R.; Kay, E.W.; Longley, D.B.; Johnston, P.G. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin. Cancer Res. 2010, 16, 3442-3451.
204. Ishimura, N.; Isomoto, H.; Bronk, S.F.; Gores, G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G129-G136.
205. Trauzold, A.; Siegmund, D.; Schniewind, B.; Sipos, B.; Egberts, J.; Zorenkov, D.; Emme, D.; Roder, C.; Kalthoff, H.; Wajant, H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25, 7434-7439.
206. Strater, J.; Hinz, U.; Hasel, C.; Bhanot, U.; Mechtersheimer, G.; Lehnert, T.; Moller, P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: Cinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005, 54, 661-665.
207. Nozoe, T.; Yasuda, M.; Honda, M.; Inutsuka, S.; Korenaga, D. Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 2003, 65, 83-88.
208. Zhang, W.; Ding, E. X.; Wang, Q.; Zhu, D.Q.; He, J.; Li, Y.L.; Wang, Y.H. Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege. World J. Gastroenterol. 2005, 11, 3632-3635.
209. Lin, M.H.; Yao, Y.H.; Yu, J.H. Expression and clinical significance of nm23-H1, Fas and FasL in colorectal carcinoma tissues. J. Sichuan Univ. Med. Sci. Edn. 2005, 36, 503-505.
210. Menon, A.G.; Morreau, H.; Tollenaar, R.A.; Alphenaar, E.; van Puijenbroek, M.; Putter, H.; Janssen-Van Rhijn, C.M.; van De Velde, C.J.; Fleuren, G.J.; Kuppen, P.J. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab. Invest. 2002, 82, 1725-1733.
211. Speetjens, F.M.; de Bruin, E.C.; Morreau, H.; Zeestraten, E.C.; Putter, H.; van Krieken, J.H.; van Buren, M.M.; van Velzen, M.; Dekker-Ensink, N.G.; van de Velde, C.J.; Kuppen, P.J. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol. Immunother. 2008, 57, 601-609.
212. Lovig, T.; Andersen, S.N.; Thorstensen, L.; Diep, C.B.; Meling, G.I.; Lothe, R.A.; Rognum, T.O. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br. J. Cancer 2002, 87, 756-762.
213. Matsushita, K.; Takenouchi, T.; Shimada, H.; Tomonaga, T.; Hayashi, H.; Shioya, A.; Komatsu, A.; Matsubara, H.; Ochiai, T. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci. 2006, 97, 57-63.
214. Sakamoto, J.; Kojima, H.; Kato, J.; Hamashima, H.; Suzuki, H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother. Pharmacol. 2000, 46, S27-S32.
215. Scott, A.M.; Lee, F.T.; Jones, R.; Hopkins, W.; MacGregor, D.; Cebon, J.S.; Hannah, A.; Chong, G.; Paul, U.; Papenfuss, A.; Rigopoulos, A.; Sturrock, S.; Murphy, R.; Wirth, V.; Murone, C.; Smyth, F.E.; Knight, S.; Welt, S.; Ritter, G.; Richards, E.; Nice, E.C.; Burgess, A.W.; Old, L.J. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 2005, 11, 4810-4817.
216. Welt, S.; Ritter, G.; Williams, C., Jr.; Cohen, L.S.; John, M.; Jungbluth, A.; Richards, E.A.; Old, L.J.; Kemeny, N.E. Phase I study of anticolon cancer humanized antibody A33. Clin. Cancer Res. 2003, 9, 1338-1346.
217. Chong, G.; Lee, F.T.; Hopkins, W.; Tebbutt, N.; Cebon, J.S.; Mountain, A.J.; Chappell, B.; Papenfuss, A.; Schleyer, P.; Paul, U.; Murphy, R.; Wirth, V.; Smyth, F.E.; Potasz, N.; Poon, A.; Davis, I.D.; Saunder, T.; O'Keefe G.J.; Burgess, A.W.; Hoffman, E.W.; Old, L.J.; Scott, A.M. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin. Cancer Res. 2005, 11, 4818-4826.
218. Welt, S.; Divgi, C.R.; Kemeny, N.; Finn, R.D.; Scott, A.M.; Graham, M.; Germain, J.S.; Richards, E.C.; Larson, S.M.; Oettgen, H.F.; et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 1994, 12, 1561-1571.
219. Fujimoto, Y.; Nakanishi, Y.; Sekine, S.; Yoshimura, K.; Akasu, T.; Moriya, Y.; Shimoda, T. CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis. Colon. Rectum. 2005, 48, 1883-1889.
220. Ohji, Y.; Yao, T.; Eguchi, T.; Yamada, T.; Hirahashi, M.; Iida, M.; Tsuneyoshi, M. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: Multivariate analysis of clinicopathological and immunohistochemical factors. Oncol. Rep. 2007, 17, 525-530.
221. Yao, T.; Takata, M.; Tustsumi, S.; Nishiyama, K.; Taguchi, K.; Nagai, E.; Tsuneyoshi, M. Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis. Pathology 2002, 34, 556-560.
222. Fujita, S.; Yamamoto, S.; Akasu, T.; Moriya, Y.; Taniguchi, H.; Shimoda, T. Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis. Anticancer Res. 2007, 27, 3307-3311.
223. Hashida, H.; Takabayashi, A.; Kanai, M.; Adachi, M.; Kondo, K.; Kohno, N.; Yamaoka, Y.; Miyake, M. Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology 2002, 122, 376-386.
224. Durrant, L.G.; Chapman, M.A.; Buckley, D.J.; Spendlove, I.; Robins, R.A.; Armitage, N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 2003, 52, 638-642.
225. Watson, N.F.; Durrant, L.G.; Madjd, Z.; Ellis, I.O.; Scholefield, J. H.; Spendlove, I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 2006, 55, 973-980.
226. Steinert, M.; Wobus, M.; Boltze, C.; Schutz, A.; Wahlbuhl, M.; Hamann, J.; Aust, G. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol. 2002, 161, 1657-1667.
227. Weichert, W.; Knosel, T.; Bellach, J.; Dietel, M.; Kristiansen, G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J. Clin. Pathol. 2004, 57, 1160-1164.
228. Kaifi, J.T.; Reichelt, U.; Quaas, A.; Schurr, P.G.; Wachowiak, R.; Yekebas, E.F.; Strate, T.; Schneider, C.; Pantel, K.; Schachner, M.; Sauter, G.; Izbicki, J.R. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod. Pathol. 2007, 20, 1183-1190.
229. Mehlen, P.; Fearon, E.R. Role of the dependence receptor DCC in colorectal cancer pathogenesis. J. Clin. Oncol. 2004, 22, 3420-3428.
230. Saito, M.; Yamaguchi, A.; Goi, T.; Tsuchiyama, T.; Nakagawara, G.; Urano, T.; Shiku, H.; Furukawa, K. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology 1999, 56, 134-141.
231. Shibata, D.; Reale, M.A.; Lavin, P.; Silverman, M.; Fearon, E.R.; Steele, G., Jr.; Jessup, J.M.; Loda, M.; Summerhayes, I.C. The DCC protein and prognosis in colorectal cancer. N. Engl. J. Med. 1996, 335, 1727-1732.
232. Miyoshi, N.; Ishii, H.; Mimori, K.; Tanaka, F.; Nagai, K.; Uemura, M.; Sekimoto, M.; Doki, Y.; Mori, M. ATP11A is a novel predictive marker for metachronous metastasis of colorectal cancer. Oncol. Rep. 2010, 23, 505-510.
233. Korkaya, H.; Wicha, M.S. Cancer stem cells: Nature versus nurture. Nat. Cell Biol. 2010, 12, 419-421.
234. Papailiou, J.; Bramis, K.J.; Gazouli, M.; Theodoropoulos, G. Stem cells in colon cancer. A new era in cancer theory begins. Int. J. Colorectal. Dis. 2010, doi:10.1007/s00384-010-1022-6.
235. Shipitsin, M.; Polyak, K. The cancer stem cell hypothesis: In search of definitions, markers, and relevance. Lab. Invest. 2008, 88, 459-463.
236. Tan, B.T.; Park, C.Y.; Ailles, L.E.; Weissman, I.L. The cancer stem cell hypothesis: A work in progress. Lab. Invest. 2006, 86, 1203-1207.
237. Vermeulen, L.; De Sousa, E.M.F.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.; Todaro, M.; Merz, C.; Rodermond, H.; Sprick, M.R.; Kemper, K.; Richel, D.J.; Stassi, G.; Medema, J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468-476.
238. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea--a paradigm shift. Cancer Res. 2006, 66, 1883-1890.
239. Pang, R.; Law, W.L.; Chu, A.C.; Poon, J.T.; Lam, C.S.; Chow, A.K.; Ng, L.; Cheung, L.W.; Lan, X.R.; Lan, H.Y.; Tan, V.P.; Yau, T.C.; Poon, R.T.; Wong, B.C. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6, 603-615.
240. Dalerba, P.; Dylla, S.J.; Park, I.K.; Liu, R.; Wang, X.; Cho, R.W.; Hoey, T.; Gurney, A.; Huang, E.H.; Simeone, D.M.; Shelton, A.A.; Parmiani, G.; Castelli, C.; Clarke, M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10158-10163.
241. Choi, D.; Lee, H.W.; Hur, K.Y.; Kim, J.J.; Park, G.S.; Jang, S.H.; Song, Y.S.; Jang, KS.; Paik, S.S. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J. Gastroenterol. 2009, 15, 2258-2264.
242. Horst, D.; Kriegl, L.; Engel, J.; Kirchner, T.; Jung, A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009, 27, 844-850.
243. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111-115.
244. Shmelkov, S.V.; Butler, J.M.; Hooper, A.T.; Hormigo, A.; Kushner, J.; Milde, T.; St. Clair, R.; Baljevic, M.; White, I.; Jin, D.K.; Chadburn, A.; Murphy, A.J.; Valenzuela, D.M.; Gale, N.W.; Thurston, G.; Yancopoulos, G.D.; D'Angelica, M.; Kemeny, N.; Lyden, D.; Rafii, S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008, 118, 2111-2120.
245. Kawasaki, B.T.; Farrar, W.L. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 2008, 29, 464-468.
246. Moreaux, J.; Veyrune, J.L.; Reme, T.; De Vos, J.; Klein, B. CD200: A putative therapeutic target in cancer. Biochem. Biophys. Res. Commun. 2008, 366, 117-122.
247. Kawasaki, B.T.; Mistree, T.; Hurt, E.M.; Kalathur, M.; Farrar, W.L. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 2007, 364, 778-782.
248. Chen, J.S.; Chen, K.T.; Fan, C.W.; Han, C.L.; Chen, Y.J.; Yu, J.S.; Chang, Y.S.; Chien, C.W.; Wu, C.P.; Hung, R.P.; Chan, E.C. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J. 2010, 277, 3028-3038.
249. Krasnov, G.S.; Oparina, N.; Khankin, S.L.; Mashkova, T.D.; Ershov, A.N.; Zatsepina, O.G.; Karpov, V.L.; Beresten, S.F. Colorectal cancer 2D-proteomics: Identification of altered protein expression. Mol. Biol. (Mosk) 2009, 43, 348-356.
250. Mazzanti, R.; Solazzo, M.; Fantappie, O.; Elfering, S.; Pantaleo, P.; Bechi, P.; Cianchi, F.; Ettl, A.; Giulivi, C. Differential expression proteomics of human colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G1329-G1338.
251. Pei, H.; Zhu, H.; Zeng, S.; Li, Y.; Yang, H.; Shen, L.; Chen, J.; Zeng, L.; Fan, J.; Li, X.; Gong, Y.; Shen, H. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res. 2007, 6, 2495-4501.
252. Xing, X.M.; Wang, Y.H.; Huang, Q.; Lu, B.J.; Lai, M.D. Differential expression of secretagogin and glucose-related protein 78 in colorectal carcinoma: A proteome study. Chin. J. Pathol. 2007, 36, 107-112.
253. Lawrie, L.C.; Curran, S. Laser capture microdissection and colorectal cancer proteomics. Methods Mol. Biol. 2005, 293, 245-253.
254. Sheehan, K.M.; Gulmann, C.; Eichler, G.S.; Weinstein, J.N.; Barrett, H.L.; Kay, E.W.; Conroy, R.M.; Liotta, L.A.; Petricoin, E.F., III. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008, 27, 323-331.
255. Kaufman, K.L.; Belov, L.; Huang, P.; Mactier, S.; Scolyer, R.A.; Mann, G.J.; Christopherson, R.I. An extended antibody microarray for surface profiling metastatic melanoma. J. Immunol. Methods 2010, 358, 23-34.
256. Ahram, M.; Litou, Z.I.; Fang, R.; Al-Tawallbeh, G. Estimation of membrane proteins in the human proteome. In Silico Biol. 2006, 6, 379-386.
257. Bitarte, N.; Bandres, E.; Zarate, R.; Ramirez, N.; Garcia-Foncillas, J. Moving forward in colorectal Cancer Res.earch, what proteomics has to tell. World J. Gastroenterol. 2007, 13, 5813-5821.
258. Yeoh, L.C.; Loh, C.K.; Gooi, B.H.; Singh, M.; Gam, L.H. Hydrophobic protein in colorectal cancer in relation to tumor stages and grades. World J. Gastroenterol. 2010, 16, 2754-2763.
259. Ikonomou, G.; Samiotaki, M.; Panayotou, G. Proteomic methodologies and their application in colorectal Cancer Res.earch. Crit. Rev. Clin. Lab. Sci. 2009, 46, 319-342.
260. Nibbe, R.K.; Chance, M.R. Approaches to biomarkers in human colorectal cancer: Looking back, to go forward. Biomark Med. 2009, 3, 385-396.
261. Soreide, K.; Nedrebo, B.S.; Knapp, J.C.; Glomsaker, T.B.; Soreide, J.A.; Korner, H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surg. Oncol. 2009, 18, 31-50.
262. Pepe, M.S.; Cai, T.; Longton, G. Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 2006, 62, 221-229.
263. Zlobec, I.; Lugli, A. Prognostic and predictive factors in colorectal cancer. J. Clin. Pathol. 2008, 61, 561-569.
264. Zlobec, I.; Minoo, P.; Baumhoer, D.; Baker, K.; Terracciano, L.; Jass, J.R.; Lugli, A. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008, 112, 495-502.
265. Fernebro, E.; Bendahl, P.O.; Dictor, M.; Persson, A.; Ferno, M.; Nilbert, M. Immunohistochemical patterns in rectal cancer: Application of tissue microarray with prognostic correlations. Int. J. Cancer 2004, 111, 921-928.
266. Lyall, M.S.; Dundas, S.R.; Curran, S.; Murray, G.I. Profiling markers of prognosis in colorectal cancer. Clin. Cancer Res. 2006, 12, 1184-1191.
267. Eckel-Passow, J.E.; Lohse, C.M.; Sheinin, Y.; Crispen, P.L.; Krco, C.J.; Kwon, E.D. Tissue microarrays: One size does not fit all. Diagn. Pathol. 2010, 5, 48-57.
268. Lal, S.; Brown, A.; Nguyen, L.; Braet, F.; Dyer, W.; Dos Remedios, C. Using antibody arrays to detect microparticles from acute coronary syndrome patients based on cluster of differentiation (CD) antigen expression. Mol. Cell Proteomics 2009, 8, 799-804.
269. Lugli, A.; Karamitopoulou, E.; Panayiotides, I.; Karakitsos, P.; Rallis, G.; Peros, G.; Iezzi, G.; Spagnoli, G.; Bihl, M.; Terracciano, L.; Zlobec, I. CD8+ lymphocytes/ tumour-budding index: An independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br. J. Cancer 2009, 101, 1382-1392.
270. Jang, T.J. Expression of E-cadherin and beta-catenin is altered at tumor budding sites, whose number is associated with the progression of colorectal carcinoma. Korean J. Pathol. 2009, 43, 523-527.
271. Hanash, S.M.; Pitteri, S.J.; Faca, V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452, 571-579.
272. Hong, B.S.; Cho, J.H.; Kim, H.; Choi, E.J.; Rho, S.; Kim, J.; Kim, J.H.; Choi, D.S.; Kim, Y.K.; Hwang, D.; Gho, Y.S. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009, 10, 556.
273. Huber, V.; Fais, S.; Iero, M.; Lugini, L.; Canese, P.; Squarcina, P.; Zaccheddu, A.; Colone, M.; Arancia, G.; Gentile, M.; Seregni, E.; Valenti, R.; Ballabio, G.; Belli, F.; Leo, E.; Parmiani, G.; Rivoltini, L. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: Role in immune escape. Gastroenterology 2005, 128, 1796-804.
274. Mrvar-Brecko, A.; Sustar, V.; Jansa, V.; Stukelj, R.; Jansa, R.; Mujagic, E.; Kruljc, P.; Iglic, A.; Hagerstrand, H.; Kralj-Iglic, V. Isolated microvesicles from peripheral blood and body fluids as observed by scanning electron microscope. Blood Cells Mol. Dis. 2010, 44, 307-312.
275. Valenti, R.; Huber, V.; Iero, M.; Filipazzi, P.; Parmiani, G.; Rivoltini, L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007, 67, 2912-2915.
276. Moritz, R.L.; Skandarajah, A.R.; Ji, H.; Simpson, R.J. Proteomic analysis of colorectal cancer: Prefractionation strategies using two-dimensional free-flow electrophoresis. Comp. Funct. Genomics 2005, 6, 236-243.
277. Qiu, Y.; Patwa, T.H.; Xu, L.; Shedden, K.; Misek, D.E.; Tuck, M.; Jin, G.; Ruffin, M.T.; Turgeon, D.K.; Synal, S.; Bresalier, R.; Marcon, N.; Brenner, D.E.; Lubman, D.M. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 2008, 7, 1693-1703.
278. Drake, P.M.; Cho, W.; Li, B.; Prakobphol, A.; Johansen, E.; Anderson, N.L.; Regnier, F.E.; Gibson, B.W.; Fisher, S.J. Sweetening the pot: Adding glycosylation to the biomarker discovery equation. Clin. Chem. 2010, 56, 223-236.
279. Fuster, M.M.; Esko, J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5, 526-542.
280. Reis, C.A.; Osorio, H.; Silva, L.; Gomes, C.; David, L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 2010, 63, 322-329.
281. Taylor, A.D.; Hancock, W.S.; Hincapie, M.; Taniguchi, N.; Hanash, S.M. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med. 2009, 1, 57.
282. Wang, H.; Tso, V.K.; Slupsky, C.M.; Fedorak, R.N. Metabolomics and detection of colorectal cancer in humans: A systematic review. Future Oncol. 2010, 6, 1395-1406.
283. Nambiar, P.R.; Gupta, R.R.; Misra, V. An Omics based survey of human colon cancer. Mutat. Res. 2010, 693, 3-18.
284. Durai, R.; Yang, S.Y.; Seifalian, A.M.; Winslet, M.C. Principles and applications of gene therapy in colon cancer. J. Gastrointest. Liver Dis. 2008, 17, 59-67.
285. Habermann, J.K.; Paulsen, U.; Roblick, U.J.; Upender, M.B.; McShane, L.M.; Korn, E.L.; Wangsa, D.; Kruger, S.; Duchrow, M.; Bruch, H.P.; Auer, G.; Ried, T. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007, 46, 10-26.